Key takeaways
- Eli Lilly's daily oral GLP-1 pill, orforglipron, demonstrated noninferior cardiovascular safety compared to insulin glargine in the Phase III ACHIEVE-4 trial.
- As a non-peptide small-molecule drug, orforglipron is shelf-stable and does not require the strict fasting or water limitations associated with current oral semaglutide.
- Gastrointestinal side effects occurred in 62.1% of patients on orforglipron and were the primary driver of treatment discontinuation.
- The trial proved cardiovascular safety, but a separate, ongoing trial (ATTAIN-Outcomes) powered to prove superior heart benefits is scheduled for completion in 2031.
What happened
At the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, researchers announced that Eli Lilly’s experimental daily weight-loss pill, orforglipron, has successfully met its primary heart safety goals. Data from the Phase III ACHIEVE-4 trial, simultaneously published in The Lancet, confirmed that the oral, non-peptide GLP-1 receptor agonist demonstrated cardiovascular safety over a median of two years when compared to injectable insulin glargine.
Why it matters
This trial represents a major milestone for the future of online medical weight loss. Today, the direct-to-consumer telehealth market is dominated by injectable peptides like Wegovy and Zepbound, or their compounded alternatives. These injections require cold-chain refrigeration, shipping with ice packs, and self-injection needles.
Orforglipron is a non-peptide small-molecule drug, meaning it is chemically synthesized rather than grown in biological systems. This structural difference makes the pill shelf-stable and dramatically simpler to manufacture at scale. For cash-paying telehealth buyers, this could eventually translate to a highly convenient daily pill that does not require strict morning fasting or water restrictions, potentially lowering the high logistical and manufacturing costs currently passed down to consumers.
What the data says
The ACHIEVE-4 trial evaluated 2,749 adults across 16 countries with type 2 diabetes and a body mass index (BMI) of 25 or higher who were already at high cardiovascular risk. Participants were randomized 1:1 to receive either daily oral orforglipron (titrated to their maximum tolerated dose) or once-daily injectable insulin glargine.
Key statistical findings reported by lead investigator Klara Klein, MD, PhD, of the University of North Carolina School of Medicine, include:
- Cardiovascular Safety: Orforglipron met noninferiority criteria for Major Adverse Cardiovascular Events (MACE). The MACE rate was 4.2% for the orforglipron group compared to 5.0% for the insulin glargine group over a median of two years.
- Secondary Benefits: Orforglipron therapy led to sustained improvements in glycemic control and body weight over 104 weeks, a 24.2% median reduction in urinary albumin-to-creatinine ratio (albuminuria) at week 52, and a slower decline in kidney function (estimated glomerular filtration rate).
- Side Effects: Gastrointestinal side effects were predictably higher with the oral GLP-1, affecting 62.1% of patients on orforglipron compared to 14.2% on insulin glargine. These gastrointestinal issues were the primary reason patients stopped taking the daily pill.
How it compares
While orforglipron has established its cardiovascular safety, it has not yet proven cardiovascular benefit in the way established injectable GLP-1 medications have. Injectables like Wegovy and Zepbound have already secured official FDA approvals for reducing major adverse cardiovascular events (such as strokes and heart attacks). In contrast, the ACHIEVE-4 trial was not statistically powered to prove superiority over insulin for heart protection.
Additionally, current oral GLP-1 options on the market, such as oral semaglutide (Rybelsus), carry strict administration instructions. Rybelsus must be taken first thing in the morning on an empty stomach with no more than four ounces of plain water, followed by a 30-minute wait before eating or drinking. Orforglipron bypasses these restrictions entirely because of its non-peptide structure, meaning users can take it at any time of day with or without food.
Compared to current pipeline alternatives, such as the early-stage candidates highlighted in the Fierce Pharma oral GLP-1 tracker, orforglipron is moving swiftly through Phase III development, positioning Eli Lilly to challenge Novo Nordisk's oral market share.
How this fits the bigger picture
For patients shopping for online weight loss programs, the development of a highly effective, shelf-stable pill could completely transform the consumer landscape. Currently, US buyers facing insurance denials frequently turn to cash-pay telehealth options, navigating the cheapest telehealth GLP-1 directories or exploring compounded vs brand-name semaglutide to manage their monthly expenses.
If approved, an easily manufactured small-molecule pill like orforglipron could ease the production bottlenecks that have triggered years of shortages. This fits into a broader clinical shift: just as our coverage on how stopping GLP-1s raises heart attack and stroke risk emphasized the dangers of therapy gaps, having a highly manufacturable, stable oral option could make long-term, uninterrupted maintenance therapy much more achievable for the average cash buyer.
What this likely means for the market is a future pricing shake-up. If Eli Lilly can produce orforglipron at a fraction of the cost of biological injectables, telehealth platforms may eventually be able to offer brand-name daily pills at prices that compete directly with today's compounded injectables.
What happens next
While the safety data from ACHIEVE-4 is a crucial step forward, proving that orforglipron actually reduces the risk of heart attacks and strokes will take several years. The ongoing ATTAIN-Outcomes clinical trial is specifically designed and statistically powered to evaluate whether orforglipron provides superior cardiovascular and kidney protection compared to a placebo. That trial is currently scheduled for completion in 2031.
In the meantime, Eli Lilly continues to advance its regulatory filings and clinical trials for orforglipron across a wide range of related conditions, including obstructive sleep apnea, osteoarthritis knee pain, and hypertension.
Disclaimer: CompareRx does not provide medical advice. Always consult with a licensed healthcare provider before starting, stopping, or changing any medication or weight-loss treatment plan.